<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267575</url>
  </required_header>
  <id_info>
    <org_study_id>G190165</org_study_id>
    <nct_id>NCT04267575</nct_id>
  </id_info>
  <brief_title>Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites</brief_title>
  <official_title>Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jerome Canady, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jerome Canady Research Institute for Advanced Biological &amp; Technological Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in&#xD;
      patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for&#xD;
      cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary&#xD;
      disease management team may be included if the metastatic disease is non-synchronous (e.g.&#xD;
      recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection)..&#xD;
      Plasma is an ionized gas typically generated in high-temperature laboratory conditions.&#xD;
      Plasma coagulators are currently used routinely as surgical tools with multiple applications&#xD;
      that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies&#xD;
      demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is&#xD;
      becoming clear that low-temperature cold plasma has an increasing role in biomedical&#xD;
      applications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2023</completion_date>
  <primary_completion_date type="Actual">April 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complications Due To Cold Plasma Application</measure>
    <time_frame>Immediate after application of cold plasma, followed by 3 months, 6 months, 12 months and 15 month observations.</time_frame>
    <description>Adverse events (CTCAE event version 4.03 to 5.0) within 30 days after Canady Helios Cold Plasma Scalpel treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Recurrent Malignant Solid Neoplasm</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage IV Fallopian Tube Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Colorectal Cancer</condition>
  <condition>Stage IV Liver Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <condition>Stage IV Lung Cancer</condition>
  <condition>Stage IV Small Intestinal Cancer</condition>
  <condition>Stage IV Gastric Cancer</condition>
  <condition>Stage IV Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Primary Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Canady Helios Cold Plasma Scalpel</intervention_name>
    <description>Device used to distribute cold plasma energy at the resected tumor margins.</description>
    <arm_group_label>Primary Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Solid tumors undergoing surgical treatment with carcinomatosis scheduled to undergo&#xD;
             surgical resection for cytoreduction. Patients with stage 4 resectable tumors as&#xD;
             decided by a multidisciplinary disease management team may be included if the&#xD;
             metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with&#xD;
             hepatic metastasis amenable for surgical resection).&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study and must be willing to return for follow-up&#xD;
&#xD;
          -  18 years of age or older and capable of providing informed consent indicating&#xD;
             awareness of the investigational nature of this trial, in keeping with Good Clinical&#xD;
             Practice (GCP) guidelines and institutional policy.&#xD;
&#xD;
          -  Biopsy (histopathology or cytology) diagnosis of a solid tumor as defined by the World&#xD;
             Health Organization (WHO) or by cross-sectional imaging reviewed by a board-certified&#xD;
             radiologist.&#xD;
&#xD;
          -  Good performance status (ECOG &lt; 2), Karnofsky &gt;60%,&#xD;
&#xD;
          -  Patients with low or acceptable surgical risk (American society of Anesthesiology&#xD;
             (ASA) score of 3 or less.&#xD;
&#xD;
          -  Patient is a candidate for surgical therapy as discussed and recommended by the&#xD;
             institutional disease management team (DMT, Tumor Board).&#xD;
&#xD;
        At the time of enrollment:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) exceeds 1200/mm3, white blood cell count exceeds&#xD;
             4000/mm3 and platelet count is greater than 100,000/mm3&#xD;
&#xD;
          -  An international normalized ratio (INR) ≤ 1.5 (patients who are therapeutically&#xD;
             anticoagulated for non-related medical conditions such as atrial fibrillation and&#xD;
             whose anti-thrombotic treatment can be withheld for operation will be eligible).&#xD;
&#xD;
          -  Adequate hepatic function must be met as evidenced by total serum bilirubin ≤ 3.0&#xD;
             mg/dl ; alkaline phosphatase &lt; 2.5 times the upper limit of normal; and, aspartate&#xD;
             aminotransferase (AST) less than 1.5 times upper limit of normal [alkaline phosphatase&#xD;
             and AST cannot both exceed the upper limit of normal]&#xD;
&#xD;
          -  Serum renal functional parameters, blood urea nitrogen (BUN) and creatinine are within&#xD;
             normal limits&#xD;
&#xD;
          -  For females of reproductive potential: use of highly effective contraception for at&#xD;
             least 1 month prior to screening and agreement to use such a method during study&#xD;
             participation.&#xD;
&#xD;
          -  Life expectancy of at least six months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          -  Patients with unresectable tumors as decided by a multidisciplinary disease management&#xD;
             team&#xD;
&#xD;
          -  Patients with multiple metastatic sites not amenable for surgical resection&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients with low performance status (ECOG &gt; 2 or Karnofsky &lt; 60%)&#xD;
&#xD;
          -  Any one or more of the following hematological abnormalities&#xD;
&#xD;
          -  Hgb &lt; 8gm/dl unable to be corrected with transfusion&#xD;
&#xD;
          -  Absolute Neutrophil Count &lt; 1200/mm3&#xD;
&#xD;
          -  White blood cell count &lt; 4000/mm3&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm3&#xD;
&#xD;
          -  INR &gt; 1.5 (except in patients who are therapeutically AST anticoagulated for&#xD;
             non-related medical conditions such as atrial fibrillation and whose anti-thrombotic&#xD;
             treatment cannot be withheld for operation will be eligible)&#xD;
&#xD;
          -  History of hepatic cirrhosis or present hepatic dysfunction&#xD;
&#xD;
          -  Alkaline phosphatase ≥ 2.5 times the upper limit of normal&#xD;
&#xD;
          -  ≥ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Serum bilirubin &gt; 3.0 mg/dl&#xD;
&#xD;
          -  Alkaline phosphatase and AST both exceed the upper limit of normal&#xD;
&#xD;
          -  Renal insufficiency indicated by a serum creatinine &gt;1.5mg/dL.&#xD;
&#xD;
          -  Patients with high surgical risk (ASA 4-5) with significant history of a medical&#xD;
             problem that would preclude the patient from undergoing an operative procedure such as&#xD;
             a history of severe congestive heart failure or active ischemic heart disease.&#xD;
&#xD;
          -  Febrile illness within 7 days before scheduled surgery&#xD;
&#xD;
          -  Treatment with another investigational drug or other intervention within 60 days&#xD;
             before surgery&#xD;
&#xD;
          -  Patients that are unable to- or unwilling to provide a written informed consent&#xD;
&#xD;
          -  Patients who underwent treatment with cold plasma within a year before study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Canady Surgical Group PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <results_first_submitted>July 16, 2021</results_first_submitted>
  <results_first_submitted_qc>July 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jerome Canady Research Institute for Advanced Biological &amp; Technological Sciences</investigator_affiliation>
    <investigator_full_name>Jerome Canady, M.D.</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04267575/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04267575/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary Arm</title>
          <description>After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.&#xD;
Canady Helios Cold Plasma Scalpel: Device used to distribute cold plasma energy at the resected tumor margins.&#xD;
Post-operatively, patients will be started back on Adjuvant chemotherapy, radiation, or immuno-therapy as per medical oncology and multi-disciplinary team.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary Arm</title>
          <description>After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.&#xD;
Canady Helios Cold Plasma Scalpel: Device used to distribute cold plasma energy at the resected tumor margins.&#xD;
Post-operatively, patients will be started back on Adjuvant chemotherapy, radiation, or immuno-therapy as per medical oncology and multi-disciplinary team.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>The population was split between 2 institutional medical centers. The study was started in Israel, and completed in the United States.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Metastatic Recurrent Colon Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Ovarian Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Anal Squamous Carcinoma to the Liver (HPV Related)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Mesothelioma to the abdominal wall</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Colon Cancer to the retroperitoneum</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Myxofibrosarcoma to the chest wall</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Breast Carcinoma to the right hip</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Non-Small cell lung Adenocarcinoma to the left/hip/upper end of femur</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Renal Cell Carcinoma to the left clavicle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Cholangiocarcinoma to the left elbow/distal humerus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Non-Small Cell Lung Carcinoma (NSCLC) to right hip</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Pleomorphic Sarcoma to the left distal femur</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Chordoma to the right gluteal posterior thigh</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Melanoma to the left pelvis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Pleomorphic Spindle Cell Sarcoma to the humerus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Squamous Cell Carcinoma to the left hand and left axillary lymph node</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Angiosarcoma of the right breast to the contralateral left breast and axilla</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Non-Small Cell Lung Carcinoma (NSCLC) to the left hemipelvis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Desmoplastic Small Round Cell Sarcoma (DSRCS) of left inguinal lymph node and testicle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic Recurrent Adenoid Cystic Carcinoma of the neck</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complications Due To Cold Plasma Application</title>
        <description>Adverse events (CTCAE event version 4.03 to 5.0) within 30 days after Canady Helios Cold Plasma Scalpel treatment.</description>
        <time_frame>Immediate after application of cold plasma, followed by 3 months, 6 months, 12 months and 15 month observations.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary Arm</title>
            <description>After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.&#xD;
Canady Helios Cold Plasma Scalpel: Device used to distribute cold plasma energy at the resected tumor margins.&#xD;
Post-operatively, patients will be started back on Adjuvant chemotherapy, radiation, or immuno-therapy as per medical oncology and multi-disciplinary team.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complications Due To Cold Plasma Application</title>
          <description>Adverse events (CTCAE event version 4.03 to 5.0) within 30 days after Canady Helios Cold Plasma Scalpel treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of participants with complications secondary to cold plasma application</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of patients receiving cold plasma application.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data has been collected for 16 months as of 5/21/21</time_frame>
      <desc>There have been 0 adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Primary Arm</title>
          <description>Patients received previous chemotherapy, radiation, immuno-therapy and/or surgery prior to metastatic recurrent disease. In this study, the patients gross solid tumor was removed, and cold plasma was sprayed in the area of the resected tumor margins.&#xD;
Canady Helios Cold Plasma Scalpel: Device used to distribute cold plasma energy at the resected tumor margins.&#xD;
Post-operatively, patients will be started back on Adjuvant chemotherapy, radiation, or immuno-therapy as per medical oncology and multi-disciplinary team.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Coronavirus Disease 2019 (COVID-19) global pandemic prolonged the duration of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jerome Canady, M.D.</name_or_title>
      <organization>Jerome Canady Research Institute for Advanced Biological and Technological Sciences</organization>
      <phone>301-270-0147</phone>
      <email>drjcanady@gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

